CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES‐I statement): an extension of the STROBE statement. Issue 1 (9th August 2016)

• Record Type: Journal Article
• Authors: Horby, Peter W.; Laurie, Karen L.; Cowling, Benjamin J.; Engelhardt, Othmar G.; Sturm‐Ramirez, Katharine; Sanchez, Jose L.; Katz, Jacqueline M.; Uyeki, Timothy M.; Wood, John; Van Kerkhove, Maria D.
• Is Part Of: Influenza and other respiratory viruses. Volume 11:Issue 1(2017)
• Page Start: 2
• Page End: 14
• Publication Date: 2016-08-09
• Subjects: Influenza -- Periodicals; Respiratory infections -- Periodicals; Virus diseases -- Periodicals; Influenza, Human -- Periodicals; Respiratory Tract Diseases -- Periodicals; Virus Diseases -- Periodicals; Grippe -- Périodiques; Appareil respiratoire -- Infections -- Périodiques; Maladies à virus -- Périodiques; 616.203
• DOI: 10.1111/irv.12411
• Languages: English
• ISSNs: 1750-2640

Abstract

Abstract : Background: Population‐based serologic studies are a vital tool for understanding the epidemiology of influenza and other respiratory viruses, including the early assessment of the transmissibility and severity of the 2009 influenza pandemic, and Middle East respiratory syndrome coronavirus. However, interpretation of the results of serologic studies has been hampered by the diversity of approaches and the lack of standardized methods and reporting. Objective: The objective of the CONSISE ROSES ‐ I statement was to improve the quality and transparency of reporting of influenza seroepidemiologic studies and facilitate the assessment of the validity and generalizability of published results. Methods: The ROSES‐I statement was developed as an expert consensus of the CONSISE epidemiology and laboratory working groups. The recommendations are presented in the familiar format of a reporting guideline. Because seroepidemiologic studies are a specific type of observational epidemiology study, the ROSES‐I statement is built upon the STROBE guidelines. As such, the ROSES‐I statement should be seen as an extension of the STROBE guidelines. Results: The ROSES ‐ I statement presents 42 items that can be used as a checklist of the information that should be included in the results of published seroepidemiologic studies, and which can also serve as a guide to the items that need to be considered during study design and implementation. Conclusions: We hope that the ROSES‐I statement will contribute to improving the quality of reporting of seroepidemiologic studies.